66. IgA腎症 ［臨床試験数：199，薬物数：214（DrugBank：57），標的遺伝子数：32，標的パスウェイ数：128］
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||NCT04525729||July 1, 2020||17/8/2020||Rituximab and RASi in Patients With IgAN||A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy||IgA Nephropathy||Drug: Rituximab;Drug: RAS 2410||CHENNAN||NULL||Recruiting||18 Years||75 Years||All||116||Phase 4||China|
|2||ChiCTR-TRC-09000338||2009-04-01||2009-02-23||Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy||Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathy||IgA nephropathy||Group A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;||The First Affiliated Hospital of Zhejiang University||NULL||Completed||18||70||Male||Group A:60;Group B:60;||China|
|3||EUCTR2005-003885-40-IT||18/10/2005||15/01/2007||ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria -||The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented |
MedDRA version: 9.1Level: SOCClassification code 10038359Term: Renal and urinary disorders
|Product Name: Ramipril|
INN or Proposed INN: Ramipril
Product Name: Irbesartan
INN or Proposed INN: Irbesartan
|AZIENDA OSPEDALIERA PROVINCIALE DI LECCO||NULL||Not Recruiting||Female: yes|